|
Basic Characteristics of Mutations
|
|
Mutation Site
|
G9081A |
|
Mutation Site Sentence
|
Analysis of the 215 database samples showed 29 samples with mutations in the viral 3'-PPT region [G9078T in one subtype F2 and one Group O;A9075T in two HIV-1 group N samples;G9081A in one HIV-1 CRF_36cpx, one HIV-1 group M/O recombinant, one HIV-1 group P, and 21 HIV-1 group O;A9071G mutation in one HIV-1 CRF02_AG sample] (Figure 5). |
|
Mutation Level
|
Nucleotide level |
|
Mutation Type
|
Synonymous substitution |
|
Gene/Protein/Region
|
LTR |
|
Standardized Encoding Gene
|
|
|
Genotype/Subtype
|
HIV-1 |
|
Viral Reference
|
HXB2
|
|
Functional Impact and Mechanisms
|
|
Disease
|
HIV Infections
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
- |
|
Location
|
Cameroon |
|
Literature Information
|
|
PMID
|
32106437
|
|
Title
|
Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy
|
|
Author
|
Acharya A,Tagny CT,Mbanya D,Fonsah JY,Nchindap E,Kenmogne L,Jihyun M,Njamnshi AK,Kanmogne GD
|
|
Journal
|
International journal of molecular sciences
|
|
Journal Info
|
2020 Feb 25;21(5):1553
|
|
Abstract
|
: Integrase strand-transfer inhibitors (INSTIs) are now included in preferred first-line antiretroviral therapy (ART) for HIV-infected adults. Studies of Western clade-B HIV-1 show increased resistance to INSTIs following mutations in integrase and nef 3'polypurine tract (3'-PPT). With anticipated shifts in Africa (where 25.6-million HIV-infected people resides) to INSTIs-based ART, it is critical to monitor patients in African countries for resistance-associated mutations (RAMs) affecting INSTIs efficacy. We analyzed HIV-1 integrase and 3'-PPT sequences in 345 clinical samples from INSTIs-naive HIV-infected Cameroonians for polymorphisms and RAMs that affect INSTIs. Phylogeny showed high genetic diversity, with the predominance of HIV-1 CRF02_AG. Major INSTIs RAMs T66A and N155K were found in two (0.6%) samples. Integrase polymorphic and accessory RAMs found included T97A, E157Q, A128T, M50I, S119R, L74M, L74I, S230N, and E138D (0.3%-23.5% of samples). Ten (3.2%) samples had both I72V+L74M, L74M+T97A, or I72V+T97A mutations; thirty-one (9.8%) had 3'-PPT mutations. The low frequency of major INSTIs RAMs shows that INSTIs-based ART can be successfully used in Cameroon. Several samples had 1 INSTIs accessory RAMs known to reduce INSTIs efficacy; thus, INSTIs-based ART would require genetic surveillance. The 3'-PPT mutations could also affect INSTIs. For patients failing INSTIs-based ART with no INSTIs RAMs, monitoring 3'-PPT sequences could reveal treatment failure etiology.
|
|
Sequence Data
|
MK327828-MK327927;MK333810-MK333910
|
|
|